FDA offers little comment on Grail cancer test ahead of adcomm
Before its advisory committee meetings, the FDA typically releases briefing documents to provide positive or negative perspective on whether a treatment works or is safe. But in the case of Wednesday's meeting of the FDA's ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.